| # | Title | Journal | Year | Citations |
|---|
| 1 | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine | 2013 | 2,426 |
| 2 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | New England Journal of Medicine | 2016 | 1,532 |
| 3 | Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia | New England Journal of Medicine | 2020 | 1,407 |
| 4 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia | Blood | 2019 | 1,254 |
| 5 | Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin | New England Journal of Medicine | 2014 | 816 |
| 6 | ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV | New England Journal of Medicine | 2014 | 669 |
| 7 | Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial | Lancet, The | 2017 | 633 |
| 8 | Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Journal of Clinical Oncology | 2017 | 596 |
| 9 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study | Lancet Oncology, The | 2018 | 551 |
| 10 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial | Lancet Oncology, The | 2018 | 530 |
| 11 | Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Journal of Clinical Oncology | 2019 | 494 |
| 12 | Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial | Blood | 2020 | 470 |
| 13 | Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy | Science Translational Medicine | 2015 | 430 |
| 14 | Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma | Blood | 2017 | 403 |
| 15 | An Interferon-free Antiviral Regimen for HCV after Liver Transplantation | New England Journal of Medicine | 2014 | 377 |
| 16 | Current state of Alzheimer’s fluid biomarkers | Acta Neuropathologica | 2018 | 370 |
| 17 | Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis | Nature Communications | 2020 | 346 |
| 18 | Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) | Nature Communications | 2018 | 344 |
| 19 | Comparison of RNA-seq and microarray-based models for clinical endpoint prediction | Genome Biology | 2015 | 325 |
| 20 | Contribution of hydrogen bonds to protein stability | Protein Science | 2014 | 323 |
| 21 | Evolution of strategies to improve preclinical cardiac safety testing | Nature Reviews Drug Discovery | 2016 | 323 |
| 22 | Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial | Lancet, The | 2018 | 316 |
| 23 | Physical chemistry of supersaturated solutions and implications for oral absorption | Advanced Drug Delivery Reviews | 2016 | 286 |
| 24 | Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet, The | 2018 | 280 |
| 25 | Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis | Journal of Hepatology | 2017 | 261 |
| 26 | Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection | Journal of Medicinal Chemistry | 2018 | 261 |
| 27 | Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease | JAMA Neurology | 2018 | 256 |
| 28 | Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective | Clinical Pharmacology and Therapeutics | 2018 | 254 |
| 29 | Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease | Gastroenterology | 2016 | 253 |
| 30 | HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease | Gastroenterology | 2020 | 249 |
| 31 | Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations | AAPS Journal | 2014 | 247 |
| 32 | Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial | Lancet, The | 2015 | 245 |
| 33 | The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma | Leukemia | 2014 | 244 |
| 34 | Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial | Journal of Allergy and Clinical Immunology | 2020 | 242 |
| 35 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study | Lancet, The | 2019 | 237 |
| 36 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial | Lancet Oncology, The | 2020 | 237 |
| 37 | Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis | JAMA Dermatology | 2021 | 236 |
| 38 | Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM | Blood | 2017 | 229 |
| 39 | Respiratory syncytial virus hospitalization and mortality: Systematic review and meta‐analysis | Pediatric Pulmonology | 2017 | 229 |
| 40 | In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) | BMC Rheumatology | 2018 | 226 |
| 41 | In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development | Clinical Pharmacology and Therapeutics | 2013 | 224 |
| 42 | A New Bliss Independence Model to Analyze Drug Combination Data | Journal of Biomolecular Screening | 2014 | 207 |
| 43 | Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy | Cancer Cell | 2017 | 206 |
| 44 | Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results | Movement Disorders | 2015 | 199 |
| 45 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial | Lancet, The | 2019 | 198 |
| 46 | Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis | Clinical Gastroenterology and Hepatology | 2018 | 191 |
| 47 | Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial | Annals of the Rheumatic Diseases | 2015 | 190 |
| 48 | Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women | Gynecologic and Obstetric Investigation | 2017 | 190 |
| 49 | Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes | Molecular Cancer Therapeutics | 2019 | 190 |
| 50 | Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease | Gastroenterology | 2020 | 189 |
